Stockreport

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 [Yahoo! Finance]

BioAtla, Inc.  (BCAB) 
PDF company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, tod [Read more]